A phase I dose-escalation study of NK012 administered intravenously as a single dose every three weeks in patients with refractory solid tumors
Latest Information Update: 10 Nov 2021
At a glance
- Drugs NK 012 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Nippon Kayaku
- 23 Oct 2007 New trial record.